Oncology – Page 29

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY 10/15/2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety profile, suggesting a viable alternative treatment approach.

Hematology-Oncology news Oncology

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

By MedXY 10/14/2025

Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a promising therapeutic strategy.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

Hematology-Oncology Oncology Specialties

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

By MedXY 10/14/2025

A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T therapy selection.

Hematology-Oncology news Oncology

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

By MedXY 10/14/2025

Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal residual disease outcomes.

Hematology-Oncology news Oncology

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

By MedXY 10/14/2025

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in advanced ISS stages and select genetic subgroups.

Hematology-Oncology news Oncology

Preclinical Progress of Glofitamab Combinations: Pioneering Therapeutics in Non-Hodgkin Lymphoma Management

By MedXY 10/14/2025

Glofitamab, a CD20×CD3 T-cell engager, demonstrates promising synergistic effects in combination with chemotherapy and novel immunotherapies, addressing resistance mechanisms in non-Hodgkin lymphoma preclinical models and supporting future clinical investigation.

Hematology-Oncology news Oncology

Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients

By MedXY 10/10/2025

The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherapy-free standard of care.

news Oncology Radiology Urology

Biparametric MRI Matches Multiparametric MRI for Prostate Cancer Diagnosis: Insights from the PRIME Trial

By MedXY 10/10/2025

The PRIME trial demonstrates that biparametric MRI, omitting contrast enhancement, is noninferior to multiparametric MRI in detecting clinically significant prostate cancer, offering a faster, cost-effective alternative potentially transforming diagnostic pathways worldwide.

news Oncology

Quantifying Breast Cancer Risk: The Impact of Pathogenic Variants and Family History in US Women

By MedXY 10/10/2025

This study evaluates cumulative breast cancer risks among US women based on pathogenic variant status and family history, revealing significant risk stratification that informs personalized screening and prevention.

Cardiology news Oncology

Long-Term Risk Factors for Valvular Heart Disease in Childhood Cancer Survivors: Insights from a European Case-Control Study

By MedXY 10/10/2025

Heart radiation, anthracyclines, and platinum chemotherapy significantly increase the risk of valvular heart disease decades after childhood cancer treatment, highlighting the need for vigilant, lifelong cardiac monitoring in survivors.

Clinical Updates Gastroenterology Oncology Radiology Specialties

Diagnostic Accuracy of MRI and CT in Evaluating Nonviability of Disappearing Colorectal Liver Metastases: An International Prospective Study

By MedXY 10/10/2025

Combining MRI and CT improves detection of nonviable disappearing colorectal liver metastases but does not reliably confirm nonviability, challenging the management of such lesions post-chemotherapy.

Gastroenterology news Oncology

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

By MedXY 10/09/2025

Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful monitoring despite low PAGE-B scores.

General Surgery news Oncology

Minimally Invasive Surgery for Left-Sided Pancreatic Cancer: Long-Term Safety Confirmed by DIPLOMA Trial

By MedXY 10/09/2025

The DIPLOMA trial demonstrates that minimally invasive left pancreatectomy for resectable pancreatic cancer offers comparable long-term survival outcomes to open surgery, validating its oncologic safety and supporting its use in clinical practice.

Oncology Public Health

Rising Incidence of Breast Cancer Among Young Women: Trends and Implications from 1990 to 2023

By MedXY 10/09/2025

Early-onset breast cancer incidence in France has steadily increased over the past three decades, mirroring trends in other Western countries. Shifts in hormonal and lifestyle factors may contribute, highlighting the need for adapted prevention and screening strategies.

Family Medicine & Nutrition news Oncology

Decoding the Rise in Early-Onset Cancer: Implications for Primary Care and Screening Strategies

By MedXY 10/09/2025

Rising early-onset cancer incidence appears driven largely by increased diagnostic scrutiny and overdiagnosis rather than a true surge in disease, altering screening and management approaches in primary care.

Gastroenterology news Oncology

Menopausal Hormone Therapy and Reduced Risk of Upper Gastrointestinal Cancers: Insights From a Large Nordic Population Study

By MedXY 10/08/2025

A large Nordic study finds menopausal hormone therapy reduces the risk of esophageal and gastric cancers by up to 30%, especially with combined estrogen-progestin systemic formulations.

news Oncology Urology

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort

By MedXY 10/05/2025

Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment access and awareness.

news OB/GYN & Women's Health Oncology Radiology Specialties

Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer

By MedXY 10/04/2025

This cohort study reveals that women with screen-detected breast cancer who missed the immediate prior mammography screening have larger tumors, more advanced disease, and worse breast cancer-specific survival, suggesting delayed detection and poorer prognosis.

General Surgery news Oncology

Defining Cure in Stage II-III Colon Cancer: Insights from a Pooled Analysis of 15 Randomized Trials

By MedXY 10/04/2025

A rigorous pooled analysis of over 35,000 patients identifies a recurrence risk below 0.5% at 6 years post-surgery, providing a practical benchmark for defining cure in stage II-III colon cancer and refining patient management strategies.